Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis
Wertheim, Gerald , Yang, Thomas, Ramne, Anna, Liu, Zhandong , Gardner, Heather Perry, Dugan, Katherine D., Kristel, Petra, Kreike, Bas , Vijver, Marc J. van de , Cardiff, Robert D. , Reynolds, Carol, Pan, Tien-Chi , Chodosh, Lewis A.

Mayo Clinic

Proceedings of the National Academy of Sciences | August 28, 2009 | Volume: 106 | Issue: 37 | Pages: 15855-15860

10.1073/pnas.0906993106 | PMID 19717424 Get It

We previously identified a SNF1/AMPK-related protein kinase, Hunk, from a mammary tumor arising in an MMTV-neu transgenic mouse. The function of this kinase is unknown. Using targeted deletion in mice, we now demonstrate that Hunk is required for the metastasis of c-myc-induced mammary tumors, but is dispensable for normal development. Reconstitution experiments revealed that Hunk is sufficient to restore the metastatic potential of Hunk-deficient tumor cells, as well as defects in migration and invasion, and does so in a manner that requires its kinase activity. Consistent with a role for this kinase in the progression of human cancers, the human homologue of Hunk is overexpressed in aggressive subsets of carcinomas of the ovary, colon, and breast. In addition, a murine gene expression signature that distinguishes Hunk-wild type from Hunk-deficient mammary tumors predicts clinical outcome in women with breast cancer in a manner consistent with the pro-metastatic function of Hunk in mice. These findings identify a direct role for Hunk kinase activity in metastasis and establish an in vivo function for this kinase.
Fibroepithelial Polyps of the Ureter: A Single-Institutional Experience
Childs, M. Adam, Umbreit, Eric , Krambeck, Amy E. , Sebo, Thomas J., Patterson, David E., Gettman, Matthew T.

Mayo Clinic

Journal of Endourology | August 28, 2009 | Volume: 23 | Issue: 9 | Pages: 1415-1419

10.1089/end.2009.0403 | PMID 19715398 Get It

Vascular-Directed Tissue Factor Pathway Inhibitor Overexpression Regulates Plasma Cholesterol and Reduces Atherosclerotic Plaque Development
Pan, Shuchong, White, Thomas A. , Witt, Tyra A. , Chiriac, Anca , Mueske, Cheri S., Simari, Robert D.

Mayo Clinic

Circulation Research | August 28, 2009 | Volume: 105 | Issue: 7 | Pages: 713-720

10.1161/circresaha.109.195016 | PMID 19713537 Get It

Rationale: Tissue factor pathway inhibitor (TFPI) is a potent regulator of the tissue factor pathway and is found in plasma in association with lipoproteins. Objective: To determine the role of TFPI in the development of atherosclerosis, we bred mice which overexpress TFPI into the apolipoprotein E–deficient (apoE −/− ) background. Methods and Results: On a high-fat diet, smooth muscle 22α (SM22α)-TFPI/apoE −/− mice were shown to have less aortic plaque burden compared to apoE −/− mice. Unexpectedly, SM22α-TFPI/apoE −/− had lower plasma cholesterol levels compared to apoE −/− mice. Furthermore, SM22α-TFPI mice fed a high-fat diet had lower cholesterol levels than did wild-type mice. Because TFPI is associated with lipoproteins and its carboxyl terminus (TFPIct) has been shown to be a ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothesized that TFPI overexpression may regulate lipoprotein distribution. We quantified VLDL binding and uptake in vitro in mouse aortic smooth muscle cells from SM22α-TFPI and wild-type mice. Mouse aortic smooth muscle cells from SM22α-TFPI mice demonstrated higher VLDL binding and internalization compared to those from wild-type mice. Because SM22α-TFPI mice have increased circulating levels of TFPI antigen, we examined whether TFPIct may act to alter lipoprotein distribution. In vitro, TFPIct increased VLDL binding, uptake, and degradation in murine embryonic fibroblasts. Furthermore, this effect was blocked by heparinase treatment. In vivo, systemic administration of TFPIct reduced plasma cholesterol levels in apoE −/− mice. Conclusions: These studies suggest that overexpression of TFPI lowers plasma cholesterol through the interaction of its carboxyl terminus with lipoproteins and heparan sulfate proteoglycans.
Bone Marrow Changes on MRI: Self-Assessment Module
Roberts, Catherine C. , Morrison, William B. , Bancroft, Laura W. , Chew, Felix S.

Mayo Clinic

American Journal of Roentgenology | August 20, 2009 | Volume: 193 | Issue: 3_supplement | Pages: S5-S9

10.2214/ajr.07.7088 | PMID 19696246 Get It

Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Lu, Kan , Zhu, Shaojun , Cvrljevic, Anna N. , Huang, Tiffany , Sarkaria, Shawn , Ahkavan, David, Dinca, Eduard B., Plaisier, Seema B. , Oderberg, Isaac M. , Chen, Zugen, Caldwell, Jeremy S. , Xie, Yongmin, Loo, Joseph A. , Seligson, David B., Chakravari, Arnab, Lee, Francis Y. , Weinmann, Roberto, Nelson, Stanley F., Bergers, Gabriele , Graeber, Thomas G. , Furnari, Frank B. , James, C. David , Cavenee, Webster K. , Johns, Terrance G. , Nelson, Stanley F. , Dang, Julie H. T. , Lee, Yohan , Cloughesy, Timothy F. , Mischel, Paul S.

Mayo Clinic

Cancer Research | August 19, 2009 | Volume: 69 | Issue: 17 | Pages: 6889-6898

10.1158/0008-5472.can-09-0347 | PMID 19690143 Get It

Abstract Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived. We show that the Src family kinases (SFK) Fyn and Src are effectors of oncogenic EGFR signaling, enhancing invasion and tumor cell survival in vivo. Expression of a constitutively active EGFR mutant, EGFRvIII, resulted in activating phosphorylation and physical association with Src and Fyn, promoting tumor growth and motility. Gene silencing of Fyn and Src limited EGFR- and EGFRvIII-dependent tumor cell motility. The SFK inhibitor dasatinib inhibited invasion, promoted tumor regression, and induced apoptosis in vivo, significantly prolonging survival of an orthotopic glioblastoma model expressing endogenous EGFRvIII. Dasatinib enhanced the efficacy of an anti-EGFR monoclonal antibody (mAb 806) in vivo, further limiting tumor growth and extending survival. Examination of a large cohort of clinical samples showed frequent coactivation of EGFR and SFKs in glioblastoma patients. These results establish a mechanism linking EGFR signaling with Fyn and Src activation to promote tumor progression and invasion in vivo and provide rationale for combined anti-EGFR and anti-SFK targeted therapies. [Cancer Res 2009;69(17):6889–98]
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
Wada, David A., Ziesmer, Steven C., Elsawa, Sherine F. , Comfere, Nneka I. , Dietz, Allan B. , Novak, Anne J. , Feldman, Andrew L. , Pittelkow, Mark R. , Ansell, Stephen M. , Wilcox, Ryan A. , Witzig, Thomas E. , Feldman, Andrew L , Elsawa, Sherine F , Dietz, Allan B

Mayo Clinic

Blood | August 12, 2009 | Volume: 114 | Issue: 14 | Pages: 2936-2944

10.1182/blood-2009-05-220111 | PMID 19671921 Get It

A variety of nonmalignant cells present in the tumor microenvironment promotes tumorigenesis by stimulating tumor cell growth and metastasis or suppressing host immunity. The role of such stromal cells in T-cell lymphoproliferative disorders is incompletely understood. Monocyte-derived cells (MDCs), including professional antigen-presenting cells such as dendritic cells (DCs), play a central role in T-cell biology. Here, we provide evidence that monocytes promote the survival of malignant T cells and demonstrate that MDCs are abundant within the tumor microenvironment of T cell–derived lymphomas. Malignant T cells were observed to remain viable during in vitro culture with autologous monocytes, but cell death was significantly increased after monocyte depletion. Furthermore, monocytes prevent the induction of cell death in T-cell lymphoma lines in response to either serum starvation or doxorubicin, and promote the engraftment of these cells in nonobese diabetic/severe combined immunodeficient mice. Monocytes are actively recruited to the tumor microenvironment by CCL5 (RANTES), where their differentiation into mature DCs is impaired by tumor-derived interleukin-10. Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders.
Association of serum myeloperoxidase with the ankle–brachial index and peripheral arterial disease
Ali, Zeenat, Sarcia, Paul J., Kondragunta, Venkateswarlu, Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Vascular Medicine | August 3, 2009 | Volume: 14 | Issue: 3 | Pages: 215-220

10.1177/1358863x08101999 | PMID 19651670 Get It

Abstract Myeloperoxidase (MPO) is an enzymatic mediator of several inflammatory cascades and higher serum levels have been associated with increased risk of adverse cardiovascular events. We investigated the association of serum MPO with the ankle–brachial index (ABI) and peripheral arterial disease (PAD) in a bi-ethnic cohort of African-Americans and non-Hispanic white individuals. Participants included 1324 African-Americans (mean age 64 years, 71% women) and 1237 non-Hispanic white individuals (mean age 59 years, 57% women) belonging to hypertensive sibships. Serum levels of MPO were measured by solid phase sandwich immunoassay. ABI was measured using a standard protocol and PAD was defined as an ABI < 0.90. Multivariable regression analysis using generalized estimating equations were performed to assess whether serum MPO levels were associated with ABI and the presence of PAD. After adjustment for age and sex, higher MPO levels were significantly associated with lower ABI and the presence of PAD in African-Americans ( p = 0.004 and p = 0.005, respectively) and in non-Hispanic white individuals ( p = 0.001 and p = 0.016, respectively). After additional adjustment for conventional risk factors (diabetes, smoking status, total and high-density lipoprotein cholesterol, waist circumference, hypertension), prior history of myocardial infarction or stroke, and medication use (statins, aspirin, estrogen), higher MPO levels remained significantly associated with lower ABI and the presence of PAD in both African-Americans ( p = 0.008 and p = 0.010, respectively) and non-Hispanic white individuals ( p = 0.001 and p = 0.018, respectively). We conclude that higher MPO levels are associated with lower ABI and the presence of PAD in African-Americans and non-Hispanic white individuals.
Tissue Factor Pathway Inhibitor Overexpression Inhibits Hypoxia-Induced Pulmonary Hypertension
White, Thomas A. , Witt, Tyra A. , Pan, Shuchong, Mueske, Cheryl S., Kleppe, Laurel S., Holroyd, Eric, Champion, Hunter C., Simari, Robert D.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | July 31, 2009 | Volume: 43 | Issue: 1 | Pages: 35-45

10.1165/rcmb.2009-0144oc | PMID 19648471 Get It

Abstract Pulmonary hypertension (PH) is a commonly recognized complication of chronic respiratory disease. Enhanced vasoconstriction, pulmonary vascular remodeling, and in situ thrombosis contribute to the increased pulmonary vascular resistance observed in PH associated with hypoxic lung disease. The tissue factor pathway regulates fibrin deposition in response to acute and chronic vascular injury. We hypothesized that inhibition of the tissue factor pathway would result in attenuation of pathophysiologic parameters typically associated with hypoxia-induced PH. We tested this hypothesis using a chronic hypoxia–induced murine model of PH using mice that overexpress tissue factor pathway inhibitor (TFPI) via the smooth muscle–specific promoter SM22 (TFPISM22). TFPISM22 mice have increased pulmonary TFPI expression compared with wild-type (WT) mice. In WT mice, exposure to chronic hypoxia (28 d at 10% O2) resulted in increased systolic right ventricular and mean pulmonary arterial pressures, changes that were significantly reduced in TFPISM22 mice. Chronic hypoxia also resulted in significant pulmonary vascular muscularization in WT mice, which was significantly reduced in TFPISM22 mice. Given the pleiotropic effects of TFPI, autocrine and paracrine mechanisms for these hemodynamic effects were considered. TFPISM22 mice had less pulmonary fibrin deposition than WT mice at 3 days after exposure to hypoxia, which is consistent with the antithrombotic effects of TFPI. Additionally, TFPISM22 mice had a significant reduction in the number of proliferating (proliferating cell nuclear antigen positive) pulmonary vascular smooth muscle cells compared with WT mice, which is consistent with in vitro findings. These findings demonstrate that overexpression of TFPI results in improved hemodynamic performance and reduced pulmonary vascular remodeling in a murine model of hypoxia-induced PH. This improvement is in part due to the autocrine and paracrine effects of TFPI overexpression.
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Ansell, Stephen M. , Novak, Anne J. , Kumar, Shaji , Gupta, Mamta , Kaufmann, Scott H. , Witzig, Thomas E.

Mayo Clinic

Blood | July 30, 2009 | Volume: 114 | Issue: 14 | Pages: 2926-2935

10.1182/blood-2009-05-220889 | PMID 19641186 Get It

The mammalian target of rapamycin (mTOR) has emerged as an important therapeutic target for diffuse large B-cell lymphoma (DLBCL), as recent studies have demonstrated that 30% of relapsed patients respond to mTOR inhibitors. Why some lymphomas are resistant is incompletely understood. In the present study, we demonstrated that rapamycin inhibits mTORC1 in DLBCL lines and primary tumors but is minimally cytotoxic. Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance. Furthermore, knockdown of the mTORC2 component rictor, but not the mTORC1 component raptor, inhibited rapamycin-induced Akt phosphorylation in lymphoma cells. Addition of the histone deacetylase inhibitor (HDI) LBH589 (LBH) overcame rapamycin resistance by blocking mTOR, thus preventing Akt activation. Further studies support the involvement of the protein phosphatase PP1 in LBH-mediated Akt dephosphorylation, which could be mimicked by knockdown of HDAC3. This is the first demonstration that a HDI such as LBH can overcome rapamycin resistance through a phosphatase that antagonizes mTORC2 activation. These results provide a mechanistic rationale for a clinical trial of a combination of HDI and mTOR inhibitors for DLBCL.